250 related articles for article (PubMed ID: 28641556)
1. Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
Andriguetti NB; Raymundo S; Antunes MV; Perassolo MS; Verza SG; Suyenaga ES; Linden R
Curr Med Chem; 2017; 24(33):3559-3582. PubMed ID: 28641556
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of the taxanes including nab-paclitaxel.
Joerger M
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Krens SD; McLeod HL; Hertz DL
Pharmacogenomics; 2013 Apr; 14(5):555-74. PubMed ID: 23556452
[TBL] [Abstract][Full Text] [Related]
4. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review.
de Weger VA; Beijnen JH; Schellens JH
Anticancer Drugs; 2014 May; 25(5):488-94. PubMed ID: 24637579
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacology of the taxanes: implications of the differences.
Gligorov J; Lotz JP
Oncologist; 2004; 9 Suppl 2():3-8. PubMed ID: 15161985
[TBL] [Abstract][Full Text] [Related]
6. Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model.
Berveiller P; Vinot C; Mir O; Broutin S; Deroussent A; Seck A; Camps S; Paci A; Gil S; Tréluyer JM
Am J Obstet Gynecol; 2012 Dec; 207(6):514.e1-7. PubMed ID: 23174392
[TBL] [Abstract][Full Text] [Related]
7. In vivo imaging as a pharmacodynamic marker.
van der Veldt AA; Lammertsma AA
Clin Cancer Res; 2014 May; 20(10):2569-77. PubMed ID: 24831279
[TBL] [Abstract][Full Text] [Related]
8. Update on taxane development: new analogs and new formulations.
Yared JA; Tkaczuk KH
Drug Des Devel Ther; 2012; 6():371-84. PubMed ID: 23251087
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned from development of docetaxel.
Strother RM; Sweeney C
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):1007-19. PubMed ID: 18624687
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
Jabir RS; Naidu R; Annuar MA; Ho GF; Munisamy M; Stanslas J
Pharmacogenomics; 2012 Dec; 13(16):1979-88. PubMed ID: 23215890
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
de Bree E; Rosing H; Michalakis J; Romanos J; Relakis K; Theodoropoulos PA; Beijnen JH; Georgoulias V; Tsiftsis DD
Eur J Surg Oncol; 2006 Aug; 32(6):666-70. PubMed ID: 16618534
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel: overview of an active drug for breast cancer.
Crown J
Oncologist; 2001; 6 Suppl 3():1-4. PubMed ID: 11346677
[TBL] [Abstract][Full Text] [Related]
14. Dosing considerations for obese patients receiving cancer chemotherapeutic agents.
Hall RG; Jean GW; Sigler M; Shah S
Ann Pharmacother; 2013 Dec; 47(12):1666-74. PubMed ID: 24259627
[TBL] [Abstract][Full Text] [Related]
15. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
[TBL] [Abstract][Full Text] [Related]
16. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
17. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers.
Arai T; Miyoshi Y; Kim SJ; Akazawa K; Maruyama N; Taguchi T; Tamaki Y; Noguchi S
Eur J Surg Oncol; 2008 Jul; 34(7):734-8. PubMed ID: 17764884
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
Esposito M; Venturini M; Vannozzi MO; Tolino G; Lunardi G; Garrone O; Angiolini C; Viale M; Bergaglio M; Del Mastro L; Rosso R
J Clin Oncol; 1999 Apr; 17(4):1132. PubMed ID: 10561171
[TBL] [Abstract][Full Text] [Related]
19. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
[TBL] [Abstract][Full Text] [Related]
20. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
de Graan AJ; Loos WJ; Friberg LE; Baker SD; van der Bol JM; van Doorn L; Wiemer EA; van der Holt B; Verweij J; Mathijssen RH
Clin Cancer Res; 2012 Aug; 18(16):4425-32. PubMed ID: 22645049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
